Back to results
US 7,479,504 B2Granted
Edg receptor agonists
AssigneeMerck & Co., Inc.
InventorsRobert L. Bugianesi, George A. Doherty, Amy Gentry, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
Life of this patent
Estimating the term…
Abstract
The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Claims5
A compound represented by Formula II
- or a pharmaceutically acceptable salt or hydrate thereof, wherein:
- n=0 or 1;
- R3 is selected from the group consisting of:
- hydrogen and C1-4alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:
- halo and hydroxy;
- each R4 is independently selected from the group consisting of:
- halo, C1-4alkyl and C1-3alkoxy, said C1-4alkyl and C1-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.
4 more elements
Dependencies are inferred from the claim text.